Cargando…
A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491044/ https://www.ncbi.nlm.nih.gov/pubmed/34975069 http://dx.doi.org/10.4103/aja202189 |
_version_ | 1784793211031519232 |
---|---|
author | Zhang, Ming Che, Ji-Zhong Liu, Yi-Dong Wang, Hong-Xiang Huang, Yan-Ping Lv, Xiang-Guo Liu, Wei Lu, Mu-Jun |
author_facet | Zhang, Ming Che, Ji-Zhong Liu, Yi-Dong Wang, Hong-Xiang Huang, Yan-Ping Lv, Xiang-Guo Liu, Wei Lu, Mu-Jun |
author_sort | Zhang, Ming |
collection | PubMed |
description | Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) and penile length in the non-erectile state (PLNES) following scheduled phosphodiesterase 5 inhibitor (PDE5i), vacuum erectile device (VED) treatment, and combination therapy after nsRP. One hundred patients with localized prostate cancer and normal EF were randomized to scheduled PDE5i group, VED treatment group, a combined treatment group, and the control group without any intervention. The International Index of Erectile Function-5 (IIEF-5) scores and PLNES were evaluated after 6 months and 12 months of treatment. Sexual Encounter Profile (SEP-Question 2 and SEP-Question 3) were evaluated after 12 months of treatment. Ninety-one of the 100 randomized patients completed the study. We found that the 5 mg tadalafil once a day (OaD) combined with VED can help improve IIEF-5 scores in nsRP patients after both 6 months and 12 months. VED alone or combined with tadalafil OaD can help patients maintain PLNES. VED combined with tadalafil OaD can improve the rate of successful penetration (SEP-Question 2) after 12 months. There were no significant differences in the return to target EF after 12 months among the groups. No significant correlation was noted between the variables and return to target EF (IIEF ≥ 17), and between the variables and effective shortening of the patient's penis (shortening ≥ 1 cm) after 12 months of intervention. |
format | Online Article Text |
id | pubmed-9491044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-94910442022-09-22 A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy Zhang, Ming Che, Ji-Zhong Liu, Yi-Dong Wang, Hong-Xiang Huang, Yan-Ping Lv, Xiang-Guo Liu, Wei Lu, Mu-Jun Asian J Androl Original Article Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) and penile length in the non-erectile state (PLNES) following scheduled phosphodiesterase 5 inhibitor (PDE5i), vacuum erectile device (VED) treatment, and combination therapy after nsRP. One hundred patients with localized prostate cancer and normal EF were randomized to scheduled PDE5i group, VED treatment group, a combined treatment group, and the control group without any intervention. The International Index of Erectile Function-5 (IIEF-5) scores and PLNES were evaluated after 6 months and 12 months of treatment. Sexual Encounter Profile (SEP-Question 2 and SEP-Question 3) were evaluated after 12 months of treatment. Ninety-one of the 100 randomized patients completed the study. We found that the 5 mg tadalafil once a day (OaD) combined with VED can help improve IIEF-5 scores in nsRP patients after both 6 months and 12 months. VED alone or combined with tadalafil OaD can help patients maintain PLNES. VED combined with tadalafil OaD can improve the rate of successful penetration (SEP-Question 2) after 12 months. There were no significant differences in the return to target EF after 12 months among the groups. No significant correlation was noted between the variables and return to target EF (IIEF ≥ 17), and between the variables and effective shortening of the patient's penis (shortening ≥ 1 cm) after 12 months of intervention. Wolters Kluwer - Medknow 2021-12-28 /pmc/articles/PMC9491044/ /pubmed/34975069 http://dx.doi.org/10.4103/aja202189 Text en Copyright: ©The Author(s)(2022) https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Zhang, Ming Che, Ji-Zhong Liu, Yi-Dong Wang, Hong-Xiang Huang, Yan-Ping Lv, Xiang-Guo Liu, Wei Lu, Mu-Jun A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title | A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title_full | A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title_fullStr | A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title_full_unstemmed | A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title_short | A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
title_sort | prospective randomized controlled study on scheduled pde5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491044/ https://www.ncbi.nlm.nih.gov/pubmed/34975069 http://dx.doi.org/10.4103/aja202189 |
work_keys_str_mv | AT zhangming aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT chejizhong aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT liuyidong aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT wanghongxiang aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT huangyanping aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT lvxiangguo aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT liuwei aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT lumujun aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT zhangming prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT chejizhong prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT liuyidong prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT wanghongxiang prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT huangyanping prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT lvxiangguo prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT liuwei prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy AT lumujun prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy |